Understanding oropharyngeal carcinoma and its connection to HPV
Multidimensional and Multimodal Profiling of Oropharyngeal Carcinoma
This study is trying to learn more about oropharyngeal cancer and its link to HPV by collecting blood samples from patients to see how the disease changes over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Stanford University Academic / other |
| Locations | 1 site (Palo Alto, California) |
| Trial ID | NCT05880797 on ClinicalTrials.gov |
What this trial studies
This observational study aims to enhance the understanding of the natural history of oropharyngeal carcinoma (OPC), particularly in relation to human papilloma virus (HPV). Researchers will collect blood samples from patients diagnosed with OPC before treatment and at six follow-up time points to analyze changes over time. The study focuses on both HPV-associated and non-associated cases to provide a comprehensive profile of the disease. By gathering this data, the study seeks to uncover insights that could inform future treatment strategies.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with oropharyngeal carcinoma or those with HPV-associated cancer of unknown primary origin.
Not a fit: Patients who are not willing to sign consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of oropharyngeal carcinoma, potentially enhancing patient outcomes.
How similar studies have performed: While this study employs a novel approach to profiling OPC, similar studies have shown promise in understanding cancer biology and patient outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients diagnosed with oropharyngeal carcinoma or patients with cancer of the unknown primary that is HPV associated, or possibly deemed to be originating from the oropharynx. Exclusion Criteria: * Not willing to sign consent
Where this trial is running
Palo Alto, California
- Stanford University — Palo Alto, California, United States (Recruiting)
Study contacts
- Principal investigator: Chris Holsinger, MD — Stanford University
- Study coordinator: Nikita Bedi
- Email: nbedi@stanford.edu
- Phone: (650) 723-5957
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.